The federal policies on CBD products continue to gain more structure
The US Food and Drug Administration (FDA) has been working for the past several months on the development of guidance to establish rules for cannabidiol (CBD) products, as well as on enforcement policies. To discuss this topic, the White House has set up a meeting that will take place in the next following days with three different groups from the hemp industry. The US Hemp Roundtable, the National Industrial Hemp Council (NIHC) and the Washington State-based hemp cultivator Ziese Farms are the three organizations that will meet Trump’s personnel to share information and concerns about these regulations.
The draft created by the FDA has been in the hands of the White House Office of Management and Budget (OMB) since last week; however, the details of what is contained in this draft haven’t been released yet. Late last year, the FDA issued warnings to some hemp operators for tagging their products as food items or dietary supplements without the proper authorization of the federal agency.
Now, operators have been waiting for the FDA to finish the regulations so they can start marketing products in accordance with those guidelines. In the meantime, the FDA is not putting extra pressure on these companies and it has only been focusing on companies that are advertising therapeutic potential in their products that haven’t been proven nor approved.
“My focus [at the meeting] is going to be on ensuring and urging the White House and the FDA to provide regulatory certainty for the sale of CBD products and to provide a safe harbor for products that are manufactured according to all other FDA requirements,” said general counsel for the US Hemp Roundtable Jonathan Miller in a talk with Marijuana Moment.